Conditioned media and extracellular vesicles derived from human Wharton’s jelly mesenchymal stem cells improve the in vitro maturation of immature oocytes in normal and PCOS mouse model Authors: Arezoo Solati, Sanaz Alaee, Fatemeh Zal, Zahra Khodabandeh, Mahintaj Dara, Shayesteh Mehdinejadiani, Sedigheh Bahmyari Published: 2025 ABSTRACT BackgroundThe effects of conditioned medium (CM) and extracellular vesicles (EVs) derived from human Wharton’s jelly mesenchymal stem cells (hWJMSCs) on in vitro maturation (IVM) of immature oocytes in both normal and polycystic ovary syndrome (PCOS)-induced mice were investigated. PCOS was induced in adult female NMRI mice by administering letrozole (90 μg/kg/day) via gavage for one week. Germinal vesicle (GV) oocytes were collected from both PCOS-induced and normal mice, while mature oocytes (MII) were obtained from superovulated normal mice to serve as controls. The experimental groups included 7 groups: Control (MII oocytes), 3 IVM groups (in vitro maturation of GV oocytes): IVM (with simple IVM media), IVM + CM, and IVM + EVs (IVM media supplemented with CM and EVs, respectively), and three PCOS groups (in vitro maturation of GV oocytes from PCOS-induced mice): PCOS IVM (with simple IVM media), PCOS IVM + CM, and PCOS IVM + EVs (IVM media supplemented with CM and EVs, respectively). After IVM was conducted in all groups, mature oocytes were harvested and assessed for maturation rate, morphology, viability, and gene expression profiles of key regulators (CDK1, CCNB1, MAP2K). Developmentally competent oocytes were selected using Brilliant Cresyl Blue staining and then subjected to in vitro maturation with or without CM or EVs supplementation. Nuclear maturation was evaluated via orcein staining, while viability was assessed using Trypan Blue. Morphometric parameters were measured using ImageJ software. Real-time PCR was utilized for the evaluation of gene expression of targeted genes.ResultsResults demonstrated that in BCB + oocytes, CM and EVs improved the mature oocytes compared to IVM. Oocytes from PCOS-induced mice exhibited reduced maturation and increased degeneration, which were rescued by CM and EV treatment. Gene expression analysis revealed downregulation of MAP2K, CCNB1, and CDK1 in IVM and PCOS IVM groups compared to the control group, while CM supplementation restored their expression. Oocyte diameter and viability were significantly enhanced in IVM + CM compared to IVM (P < 0.05).ConclusionsThese findings suggest that hWJMSC-derived secretomes, particularly CM, enhance oocyte maturation and quality, offering potential therapeutic benefits for IVM in both normal and PCOS conditions.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12938-025-01500-7. Introduction Polycystic ovary syndrome is a common hormone disorder that affects women during their childbearing years. The number of women diagnosed with PCOS varies depending on the set of diagnostic rules used [1]. During fertility treatments, women with PCOS typically produce more eggs when given ovary-stimulating hormones compared to women without PCOS [2]. However, because of alterations in the follicular fluid, hormonal imbalance, and oocyte microenvironment, a significant proportion of these oocytes remain immature, compromising their developmental potential [3, 4]. Currently, in vitro maturation (IVM) serves as an effective approach to rescue oocytes that fail to mature in vivo following ovarian stimulation, enabling their progression to mature oocytes at the stage of metaphase II (MII) [5]. Consequently, IVM has been proposed as a tailored approach for PCOS patients undergoing assisted reproductive techniques [6]. However, despite its potential, the clinical application of IVM remains limited due to low maturation and fertilization rates, ultimately resulting in lower pregnancy success even in non-PCOS patients [7, 8]. A key challenge in IVM lies in replicating the physiological follicular environment in vitro, as current culture conditions fail to support oocyte maturation fully [9]. The process of oocyte maturation involves coordinated signaling pathways and cell cycle regulators, including CDC2 (also known as CDK1), CCNB1 (cyclin B1), and MAP2K (MEK1/2) [10]. CDC2/CDK1, in complex with cyclin B1, forms the maturation-promoting factor (MPF), which is crucial for the germinal vesicle breakdown, spindle formation, chromosome condensation, and consequently, oocyte progression of the maturation oocyte [11]. The levels and activity of CCNB1 are tightly regulated, ensuring the timely activation and inactivation of MPF during maturation. Additionally, MAP2K (MEK1/2), part of the MAPK/ERK signaling pathway, modulates cytoplasmic and nuclear maturation processes by regulating the activity of cyclin-dependent kinases and other downstream effectors [10]. Activation of the MAPK pathway is essential for spindle assembly, oocyte cytoplasmic maturation, and successful completion of meiosis II [12]. Together, CDC2, CCNB1, and MAP2K orchestrate the intricate signaling networks that underpin oocyte maturation, ensuring the oocyte reaches developmental competence for fertilization [12]. Recent advances in IVM research have focused on optimizing culture conditions to enhance meiotic resumption and cytoplasmic maturation—two critical determinants of oocyte quality [13, 14]. In this context, novel culture medium additives have emerged as potential tools to improve oocyte maturation efficiency and developmental outcomes [15, 16]. Nowadays, mesenchymal stem cells (MSCs) are recognized as potential therapeutic agents for treating a wide range of diseases largely attributed to their capacity to secrete bioactive molecules [17]. Conditioned medium (CM) derived from MSCs has shown significant clinical relevance, as it contains a complex mixture of bioactive factors capable of exerting therapeutic effects [18]. MSC-derived CM is rich in growth factors, cytokines, and tissue regeneration mediators that can modulate in vitro maturation [13]. Extracellular vesicles (EVs) are membrane-enclosed particles present in various biological fluids, including plasma, urine, follicular fluid, and culture supernatants of MSCs [19]. The cells secrete these lipid bilayer vesicles into the extracellular environment, where they coordinate communication between cells by transporting diverse cargoes such as cytokines, proteins, microRNAs, and lipids [19]. Many of the regenerative effects associated with MSC therapy are mediated through EVs [20]. In the process of reproduction, EVs influence key reproductive processes, including oocyte maturation, sperm capacitation, fertilization, and the development and implantation of the embryo [21]. In this context, MSC-derived EVs have emerged as a particularly promising, cell-free tool for enhancing oocyte maturation and embryo development [22]. They are enriched with bioactive cargo including specific miRNAs, growth factors, and anti-inflammatory cytokines that can be directly delivered to oocytes and cumulus cells [22]. This transfer can positively remodel the follicular microenvironment and enhance cumulus cell function, which is crucial for oocyte support [23]. Also, it is shown that exosomes derived from human umbilical cord MSCs improved the quality of IVM-matured oocytes in aged mice and boosted developmental potential [24]. Consequently, supplementing IVM culture media with MSC-derived EVs has the potential to more closely mimic the natural follicular niche. Given the altered follicular environment in PCOS, we hypothesized that hWJMSC-EVs could help restore a more physiological microenvironment, thereby correcting meiotic and cytoplasmic deficiencies and leading to improved maturation rates and developmental competence in PCOS-derived oocytes. In the current study, the expected effect is the targeted enhancement of the core molecular machinery of meiosis, including the MAPK and MPF pathways, thereby promoting both nuclear and cytoplasmic maturation. The use of Wharton’s jelly provides access to a potent MSC population without the need for invasive harvesting procedures, as it is sourced from donated umbilical cords that are readily available as medical waste following live births, offering a primitive, immunomodulatory, and highly proliferative cell population that is ideal for standardized and scalable therapeutic production [25, 26]. Therefore, the IVM medium was supplemented with CM or EVs of human Wharton’s jelly mesenchymal stem cells (hWJMSCs) in a mouse model of PCOS. After conducting the IVM, the maturation rates (GV, MI, MII stages), oocyte quality parameters such as zona pellucida thickness, perivitelline space size, and oocyte diameter, oocyte morphology, viability, nuclear maturation, and the expression levels of key maturation-related genes, including CDK1, CCNB1, and MAP2K, were evaluated in mature oocytes. Results Characterization of hWJMSCs Observations with light microscopy demonstrated that the monolayer MSCs were morphologically homogeneous and spindle-shaped. Using flow cytometry, it was confirmed that the isolated cells expressed MSC markers (CD73, CD90) at high levels and hematopoietic markers (CD34, CD144) at low levels (Fig. 1A). Additionally, Oil-Red O staining revealed the presence of lipid droplets in differentiating MSCs (Fig. 1B), while Alizarin Red staining indicated calcium deposition, confirming osteoblast differentiation (Fig. 1C).Fig. 1Characterization of human Wharton’s jelly mesenchymal stem cells (hWJMSCs). A Surface marker expression profile analyzed by flow cytometry. B Adipogenic differentiation potential demonstrated by Oil-Red O staining. C Osteogenic differentiation capacity shown by Alizarin Red staining. D The TEM image of hWJMSCs-derived EVs Characterization of human Wharton’s jelly mesenchymal stem cells (hWJMSCs). A Surface marker expression profile analyzed by flow cytometry. B Adipogenic differentiation potential demonstrated by Oil-Red O staining. C Osteogenic differentiation capacity shown by Alizarin Red staining. D The TEM image of hWJMSCs-derived EVs Characterization of isolated EVs Transmission electron microscopy Using TEM microscopy, round or disk-shaped particles were seen in groups (Fig. 1D). Dynamic light scattering DLS is a method used to assess the dimensions of EVs. On average, EVs measured 17.82 nm in diameter. Testosterone level Letrozole-induced PCOS led to a significant rise in serum testosterone levels compared to the control group (P < 0.0001) (Fig. 2A).Fig. 2A Significant increase in serum testosterone levels in letrozole-induced PCOS mice compared to the control group (P < 0.001). B and C Histological sections of ovarian tissue from control and PCOS mice. Yellow stars show ovarian cysts in the ovarian tissue of PCOS mice A Significant increase in serum testosterone levels in letrozole-induced PCOS mice compared to the control group (P < 0.001). B and C Histological sections of ovarian tissue from control and PCOS mice. Yellow stars show ovarian cysts in the ovarian tissue of PCOS mice Ovarian histopathology In the ovaries of mice, control follicles in different phases of development were observed; however, in the PCOS group, cystic follicles were found. Also, the PCOS mice showed significantly lower corpus luteum (Fig. 2B and C and Table 1). Table 1The number of follicles, corpus luteum and cysts in the ovarian tissue of the PCOS and control miceGroupsPrimordial folliclesPrimary folliclesSecondary folliclesGraafian folliclesAtretic folliclesCorpus luteumOvarian cystsControl9.75 ± 1.47.75 ± 0.855.80 ± 0.760.80 ± 0.410.75 ± 0.554.70 ± 0.920PCOS3.35 ± 1.08*4.0 ± 0.91*2.85 ± 1.03*0.35 ±.48*8.25 ± 1.11*0.65 ± 0.67*9.25 ± 1.16*Data are shown as mean ± SD* Significant difference between the PCOS and control groups (P < 0.001) Table 1The number of follicles, corpus luteum and cysts in the ovarian tissue of the PCOS and control miceGroupsPrimordial folliclesPrimary folliclesSecondary folliclesGraafian folliclesAtretic folliclesCorpus luteumOvarian cystsControl9.75 ± 1.47.75 ± 0.855.80 ± 0.760.80 ± 0.410.75 ± 0.554.70 ± 0.920PCOS3.35 ± 1.08*4.0 ± 0.91*2.85 ± 1.03*0.35 ±.48*8.25 ± 1.11*0.65 ± 0.67*9.25 ± 1.16*Data are shown as mean ± SD* Significant difference between the PCOS and control groups (P < 0.001) The number of follicles, corpus luteum and cysts in the ovarian tissue of the PCOS and control mice Data are shown as mean ± SD * Significant difference between the PCOS and control groups (P < 0.001) The outcomes of IVM after selecting oocytes with BCB staining The results of the BCB staining are summarized in Table 2. The PCOS IVM group exhibited a significantly lower rate of MII oocytes compared to the IVM control group (P < 0.01). Supplementation with conditioned medium significantly rescued this deficit, leading to a higher MII oocyte rate in the PCOS IVM + CM group compared to the PCOS IVM group (P < 0.05). A similar, though non-significant, improving trend was observed with EV supplementation (P > 0.05). Table 2Maturation rate of mice GV oocytes selected with BCBGroupsNo. of oocyteMII (% ± SD) No. of oocyteMI (% ± SD) No. of oocyteGV (% ± SD) No. of oocyteDeg (% ± SD) No. of oocyteIVM18262.1 ± 7.6 (113)12.1 ± 2.95 (22)15.9 ± 3.43 (29)9.9 ± 4.1 (18)IVM + CM19673.5 ± 9.8 (144)a10.2 ± 4.96 (20)8.2 ± 4.99 (16)a8.2 ± 3.9 (16)IVM + EVs20169.7 ± 7.55 (140)10.9 ± 2.28 (22)8.9 ± 3.33 (18)a10.4 ± 3.8 (21)PCOS IVM18143.1 ± 7.48 (78)a17.7 ± 3.14 (32)a19.9 ± 4.37 (36)19.3 ± 4.55 (35)aPCOS IVM + CM19057.4 ± 9.22 (109)b15.8 ± 5.09 (30)12.6 ± 3.34 (24)b14.2 ± 2.32 (27)bPCOS IVM + EVs20249.5 ± 8.49 (100)a17.8 ± 4.07 (36)17.8 ± 4.27 (36)c14.9 ± 3.51 (30)bThe results are presented as mean ± standard deviation (SD), calculated from ten independent biological replicates for each group and maturation stagea Significant difference vs IVM groupb Significant difference vs PCOS IVM group. Every experimental group was compared to the IVM group; the non-PCOS groups (IVM, IVM + CM, IVM + EVs) were compared with each other; and the PCOS groups (PCOS IVM, PCOS IVM + CM, PCOS IVM + EVs) were compared with each other Table 2Maturation rate of mice GV oocytes selected with BCBGroupsNo. of oocyteMII (% ± SD) No. of oocyteMI (% ± SD) No. of oocyteGV (% ± SD) No. of oocyteDeg (% ± SD) No. of oocyteIVM18262.1 ± 7.6 (113)12.1 ± 2.95 (22)15.9 ± 3.43 (29)9.9 ± 4.1 (18)IVM + CM19673.5 ± 9.8 (144)a10.2 ± 4.96 (20)8.2 ± 4.99 (16)a8.2 ± 3.9 (16)IVM + EVs20169.7 ± 7.55 (140)10.9 ± 2.28 (22)8.9 ± 3.33 (18)a10.4 ± 3.8 (21)PCOS IVM18143.1 ± 7.48 (78)a17.7 ± 3.14 (32)a19.9 ± 4.37 (36)19.3 ± 4.55 (35)aPCOS IVM + CM19057.4 ± 9.22 (109)b15.8 ± 5.09 (30)12.6 ± 3.34 (24)b14.2 ± 2.32 (27)bPCOS IVM + EVs20249.5 ± 8.49 (100)a17.8 ± 4.07 (36)17.8 ± 4.27 (36)c14.9 ± 3.51 (30)bThe results are presented as mean ± standard deviation (SD), calculated from ten independent biological replicates for each group and maturation stagea Significant difference vs IVM groupb Significant difference vs PCOS IVM group. Every experimental group was compared to the IVM group; the non-PCOS groups (IVM, IVM + CM, IVM + EVs) were compared with each other; and the PCOS groups (PCOS IVM, PCOS IVM + CM, PCOS IVM + EVs) were compared with each other Maturation rate of mice GV oocytes selected with BCB The results are presented as mean ± standard deviation (SD), calculated from ten independent biological replicates for each group and maturation stage a Significant difference vs IVM group b Significant difference vs PCOS IVM group. Every experimental group was compared to the IVM group; the non-PCOS groups (IVM, IVM + CM, IVM + EVs) were compared with each other; and the PCOS groups (PCOS IVM, PCOS IVM + CM, PCOS IVM + EVs) were compared with each other The IVM + CM group also showed a significantly higher MII oocyte rate than the IVM group (P < 0.05), indicating a general benefit of CM on oocyte maturation. The percentage of GV oocytes was significantly lower in the IVM + CM and IVM + EVs groups compared to the IVM group (P < 0.05 for both). This reduction in immature oocytes was also observed in the PCOS IVM + CM group relative to the PCOS IVM group (P < 0.05). Furthermore, the PCOS IVM group showed a significant increase in the percentages of both MI and degenerated oocytes compared to the IVM group (P < 0.05 for both). This adverse effect was mitigated by CM and EV supplementation, as both the PCOS IVM + CM and PCOS IVM + EVs groups had significantly fewer degenerated oocytes than the PCOS IVM group (P < 0.05 for both). Oocyte maturation rate without BCB selection of immature oocytes The study evaluated the maturation rates of oocytes across different experimental groups, with a focus on metaphase II as the primary outcome (Fig. 3 and Table 3). The IVM group showed significantly lower MII rates compared to the control group (P < 0.001).Fig. 3Representative images of oocytes at different maturation stages. Germinal vesicle (GV), germinal vesicle breakdown (GVBD), metaphase I (MI), and metaphase II (MII)Table 3Percentage of mature (MII), MI, GV, and degenerated oocytes in the immature oocytes of experimental groups selected without BCBGroupsNo. of oocyteMII (% ± SD)No. of oocyteMI (% ± SD)No. of oocytesGV (% ± SD)No. of oocytesDeg (% ± SD)No. of oocytesControl14871.6 ± 10.7 (106)9.4 ± 4.9 (14)10.8 ± 3.3 (16)8.1 ± 2.7 (12)IVM19155.0 ± 6.2 (105)a15.7 ± 2.8 (30)a14.6 ± 4.9 (28)14.6 ± 4.1 (28)IVM + CM21663.9 ± 7.5 (138)b15.3 ± 2.7 (33)a9.7 ± 2.5 (21)11.1 ± 5.2 (24)IVM + EVs17956.4 ± 7.6 (101)a13.4 ± 3.8 (24)12.8 ± 3.8 (23)17.3 ± 7.4 (31)PCOS IVM18737.9 ± 5.26 (71)a,b15.5 ± 3.6 (29)a20.8 ± 3.1 (39)a25.6 ± 6.7 (48)aPCOS IVM + CM17556 ± 7.1 (98)c12.57 ± 3.3 (22)16 ± 4.3 (28)15.4 ± 4.1 (27)a,cPCOS IVM + EVs17140.9 ± 6.2 (70)a,d18.7 ± 4.1 (32)20.4 ± 4.1 (35)a19.8 ± 6.9 (34)aThe results are presented as mean % ± standard deviation (SD), calculated from the ten independent biological replicates for each group and maturation stagea Significant difference with the control groupb Significant difference with the IVM groupc Significant difference with PCOS IVM groupd Significant difference with PCOS IVM + CM group. Every experimental group was compared to the control group. The IVM group compared to PCOS IVM group. The non-PCOS groups (IVM, IVM + CM, IVM + EVs) were compared with each other; and the PCOS groups (PCOS IVM, PCOS IVM + CM, PCOS IVM + EVs) were compared with each other Representative images of oocytes at different maturation stages. Germinal vesicle (GV), germinal vesicle breakdown (GVBD), metaphase I (MI), and metaphase II (MII) Table 3Percentage of mature (MII), MI, GV, and degenerated oocytes in the immature oocytes of experimental groups selected without BCBGroupsNo. of oocyteMII (% ± SD)No. of oocyteMI (% ± SD)No. of oocytesGV (% ± SD)No. of oocytesDeg (% ± SD)No. of oocytesControl14871.6 ± 10.7 (106)9.4 ± 4.9 (14)10.8 ± 3.3 (16)8.1 ± 2.7 (12)IVM19155.0 ± 6.2 (105)a15.7 ± 2.8 (30)a14.6 ± 4.9 (28)14.6 ± 4.1 (28)IVM + CM21663.9 ± 7.5 (138)b15.3 ± 2.7 (33)a9.7 ± 2.5 (21)11.1 ± 5.2 (24)IVM + EVs17956.4 ± 7.6 (101)a13.4 ± 3.8 (24)12.8 ± 3.8 (23)17.3 ± 7.4 (31)PCOS IVM18737.9 ± 5.26 (71)a,b15.5 ± 3.6 (29)a20.8 ± 3.1 (39)a25.6 ± 6.7 (48)aPCOS IVM + CM17556 ± 7.1 (98)c12.57 ± 3.3 (22)16 ± 4.3 (28)15.4 ± 4.1 (27)a,cPCOS IVM + EVs17140.9 ± 6.2 (70)a,d18.7 ± 4.1 (32)20.4 ± 4.1 (35)a19.8 ± 6.9 (34)aThe results are presented as mean % ± standard deviation (SD), calculated from the ten independent biological replicates for each group and maturation stagea Significant difference with the control groupb Significant difference with the IVM groupc Significant difference with PCOS IVM groupd Significant difference with PCOS IVM + CM group. Every experimental group was compared to the control group. The IVM group compared to PCOS IVM group. The non-PCOS groups (IVM, IVM + CM, IVM + EVs) were compared with each other; and the PCOS groups (PCOS IVM, PCOS IVM + CM, PCOS IVM + EVs) were compared with each other Percentage of mature (MII), MI, GV, and degenerated oocytes in the immature oocytes of experimental groups selected without BCB The results are presented as mean % ± standard deviation (SD), calculated from the ten independent biological replicates for each group and maturation stage a Significant difference with the control group b Significant difference with the IVM group c Significant difference with PCOS IVM group d Significant difference with PCOS IVM + CM group. Every experimental group was compared to the control group. The IVM group compared to PCOS IVM group. The non-PCOS groups (IVM, IVM + CM, IVM + EVs) were compared with each other; and the PCOS groups (PCOS IVM, PCOS IVM + CM, PCOS IVM + EVs) were compared with each other IVM + CM significantly improved MII rates compared to IVM alone, while IVM + EVs showed no significant improvement (P < 0.05 and P > 0.05, respectively). The PCOS IVM group had significantly lower MII rates than both the control (P < 0.0001) and standard IVM group (P < 0.001). PCOS IVM also exhibited higher GV oocytes (P < 0.0001) and degeneration rates (P < 0.0001) compared to the control. PCOS IVM + CM restored MII rates compared to PCOS IVM (P < 0.001). It also reduced degenerated oocytes (P < 0.01). PCOS IVM + EVs showed no significant improvement in MII rates (P > 0.05). Effects of secretome (CM/EVs) from hWJMSCs on nuclear maturation of oocytes Following orcein staining, it was observed that the proportion of MII oocytes was significantly lower in the IVM group compared to the control group (P < 0.0001). However, this rate increased in the IVM + CM group compared to the IVM group (P = 0.0014). Additionally, the rate was significantly higher in the IVM + CM group than in the IVM + EVs group (P < 0.05). In the PCOS group, the proportion of MII oocytes was lower compared to the non-PCOS IVM group (P < 0.05). Among PCOS samples, the IVM + CM group showed a higher rate than the PCOS IVM group (P < 0.01). The percentage of degenerated oocytes was significantly higher in the IVM group compared to the control (P < 0.01), but it was significantly reduced in the IVM + EVs group relative to the IVM group (P < 0.001). These findings are illustrated in Fig. 4.Fig. 4The percentage of MII, Ana-Tel, GVBD, GV, and degenerated oocytes after staining with aceto-orcein. Data presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 The percentage of MII, Ana-Tel, GVBD, GV, and degenerated oocytes after staining with aceto-orcein. Data presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 Effects of hWJMSCs-derived CM or EVs on the survival rate of MII oocytes Mature oocyte viability was evaluated across experimental groups (Fig. 5A). The proportion of viable metaphase II (MII) oocytes in the IVM group was significantly lower than in the control group (P < 0.0001). However, supplementation with conditioned medium (IVM + CM) or extracellular vesicles (IVM + EVs) significantly improved oocyte viability compared to IVM alone (P < 0.01 and P < 0.001, respectively).Fig. 5A Percentage of viable MII oocytes, B oocyte diameter, C zona pellucida (ZP) thickness, and D perivitelline space (PVS) diameter in different experimental groups. Data presented as mean ± SEM. **P < 0.01, ***P < 0.001 and ****P < 0.0001 A Percentage of viable MII oocytes, B oocyte diameter, C zona pellucida (ZP) thickness, and D perivitelline space (PVS) diameter in different experimental groups. Data presented as mean ± SEM. **P < 0.01, ***P < 0.001 and ****P < 0.0001 CM resulted in higher viable MII oocytes than standard IVM in the PCOS model (P < 0.0001). Conversely, both PCOS IVM + CM and PCOS IVM + EVs exhibited significantly higher oocyte viability compared to PCOS IVM (P < 0.0001 and P < 0.001, respectively). Effects of secretome (CM/EVs) from hWJMSCs on morphometric parameters of oocytes Comparative analysis of oocyte diameter across experimental groups revealed a significant reduction in the IVM group compared to the control group (P < 0.0001). However, oocyte diameter was significantly higher in the IVM + CM group than in both the IVM (P < 0.0001) and IVM + EVs (P < 0.01) groups. Furthermore, both CM and EVs in the PCOS model significantly increased oocyte diameter compared to the PCOS IVM group (P < 0.0001 for both). ZP thickness in PCOS IVM + CM decreased significantly compared to the PCOS IVM group (P < 0.01). There was no significant difference in PVS size among the studied groups (P > 0.05) (Fig. 5B–D). Effects of secretome (CM/EVs) from hWJMSCs on expression of Cdk1, Ccnb1, and Map2k Map2k transcript levels were significantly downregulated in the IVM group relative to controls (P < 0.05) and further diminished in the PCOS IVM group compared to IVM alone (P < 0.05). In contrast, supplementation of IVM with CM in the IVM led to a marked increase in Map2k expression (P < 0.01). Similarly, the PCOS IVM + CM group exhibited elevated Map2k levels compared to both PCOS IVM and PCOS IVM + EVs groups (P < 0.01 and P < 0.05, respectively). For Ccnb1, expression was significantly reduced in the IVM group versus controls (P < 0.01), while no significant difference was observed between the PCOS IVM and IVM groups (P > 0.05). Although Ccnb1 levels showed an upward trend in IVM + CM and IVM + EVs groups compared to IVM alone, this increase did not reach statistical significance (P > 0.05). However, in the PCOS IVM + CM group, Ccnb1 expression was significantly higher than in PCOS IVM (P < 0.05). Cdk1 expression was significantly lower in the IVM group than in controls (P < 0.01) and exhibited a significant increase in the IVM + CM group compared to the IVM group (P < 0.05). Notably, Cdk1 levels were further reduced in PCOS IVM compared to IVM (P < 0.01). Conversely, the PCOS IVM + CM group displayed a significant upregulation relative to PCOS IVM (P < 0.05) (Fig. 6).Fig. 6Relative gene expression level of Cdk1, Ccnb1, Map2k in different experimental groups. Data presented as mean ± SEM. *P < 0.05 and **P < 0.01 Relative gene expression level of Cdk1, Ccnb1, Map2k in different experimental groups. Data presented as mean ± SEM. *P < 0.05 and **P < 0.01 Discussion This study demonstrates that in vitro maturation efficiency is significantly compromised in both standard and PCOS models, as evidenced by reduced metaphase II oocyte yields, increased GV and degenerated oocytes, and downregulation of key maturation regulators (Cdk1, Ccnb1, and Map2k). However, supplementation with human Wharton’s jelly mesenchymal stem cell-derived conditioned medium consistently rescued oocyte competence, enhancing nuclear maturation rates, oocyte viability, and morphometric parameters (oocyte diameter and ZP thickness). Notably, BCB + oocytes treated with CM exhibited significantly higher MII rates compared to IVM alone, while PCOS IVM oocytes showed severe maturation defects, which were partially reversed by CM. EVs also improved outcomes but were less effective than CM, particularly in PCOS, where CM restored Map2k and Cdk1 expression—critical for meiotic progression. These findings highlight CM’s superior potential in optimizing IVM, especially in PCOS-associated oocyte dysfunction, likely due to its rich secretome of growth factors and regulatory molecules. The developmental potential of oocytes refers to their capacity to resume meiosis, undergo fertilization, form a blastocyst, and ultimately give rise to healthy offspring [27]. Although efforts have been made, the chances of implantation and live births remain very low for embryos developed from mature oocytes in IVM. On the other hand, research indicates that the cells in these embryos often have chromosomal abnormalities. Therefore, oocyte quality is highly important, and studies are looking for the best maturation of immature oocytes and reducing their subsequent complications [28]. To enhance the efficiency of in vitro embryo production, the initial step involves choosing high-quality, suitable immature oocytes that produce the highest quality mature oocytes when transferred to the IVM environment [29, 30]. The BCB staining method, a non-invasive technique that reveals glucose-6-phosphate dehydrogenase (G6PD) levels, is the optimal way to select immature oocytes. This enzyme is abundant in fresh, high-quality oocytes but declines as the oocyte ages [31]. Research indicates that BCB+ oocytes exhibit a higher rate of cytoplasmic maturation, improved fertilization rates, and enhanced embryo development to the blastocyst stage compared to BCB− oocytes [32]. However, it has also been shown that not every BCB+ oocyte leads to perfect embryo development, and the BCB test alone is not sufficient to identify oocytes fully competent for in vitro embryo development [33]. Moreover, some studies indicate that although the BCB dye can distinguish immature oocyte populations with varying developmental competence, no significant improvement in overall in vitro embryo production was observed when using oocytes exposed to BCB compared to those not exposed [34]. The current study revealed significant differences in maturation outcomes between BCB-selected and non-selected oocytes during IVM. BCB + oocytes demonstrated superior developmental competence, with significantly higher MII rates in both standard IVM and PCOS models compared to their non-selected counterparts. This enhanced performance was accompanied by reduced rates of degeneration and GV arrest in BCB-selected oocytes, particularly when supplemented with CM. In contrast, non-selected oocytes exhibited poorer outcomes across all parameters, including lower MII rates, higher degeneration, and increased meiotic arrest. These results collectively demonstrate that BCB selection serves as an effective screening tool that not only identifies oocytes with greater developmental potential but also enhances their responsiveness to IVM optimization strategies, particularly in challenging conditions like PCOS. The stark contrast between BCB-selected and non-selected oocytes underscores the importance of pre-IVM competence assessment for improving ART outcomes. This finding agrees with prior studies by Yan-Guang that employed the same staining technique for selecting viable immature mouse oocytes [32]. Besides, in support of our findings of better developmental potential of BCB + oocytes, Opiela et al. (2008) found that BCB+ bovine oocytes matured in vitro and then underwent in vitro fertilization (IVM/IVF) had significantly more ability to reach the 2-cell stage and blastocyst stage than BCB− oocytes in their ability [35]. Research indicates that BCB + oocytes exhibit significantly elevated mRNA levels of genes related to mitochondrial biogenesis, suggesting this could contribute to their enhanced developmental potential [30]. Overall, the study demonstrates that both CM and EVs groups showed higher MII oocyte yields compared to standard IVM for normal and PCOS mice, with CM proving more effective than EVs, likely due to its broader spectrum of soluble factors. During maturation, oocytes experience nuclear transformations, exiting the diplotene stage of the first meiotic prophase and advancing to metaphase II, while releasing the first polar body. Observing the chromosomes of oocytes at this stage provides a more dependable method for assessing the progress of in vitro maturation [36]. In this research, we conducted orcein staining for the initial time to assess nuclear maturation in mouse oocytes. Orcein staining confirmed CM’s superiority in restoring MII rates even in PCOS oocytes. PCOS oocytes exhibited significantly lower MII rates, but CM supplementation restored maturation efficiency, highlighting its potential clinical relevance for PCOS patients undergoing IVM. The viability and morphometric assessments collectively demonstrate that CM significantly enhances both oocyte survival rates and morphological parameters, key indicators of developmental competence, particularly in PCOS-derived oocytes, while EVs show more modest improvements. This consistent pattern suggests that although EVs contain essential bioactive factors, CM’s richer composition of regulatory components provides more comprehensive support for oocyte maturation by simultaneously improving viability, restoring normal diameter, and maintaining proper ZP thickness. The superior efficacy of CM under challenging conditions like PCOS highlights its multifaceted protective and maturation-promoting effects, implying that while EVs offer therapeutic potential, CM’s broader array of factors may be necessary for optimal IVM outcomes, especially in compromised oocytes. Although existing commercial IVM media are costly and show limited effectiveness, MSC-CM holds promise due to its likely paracrine effects, justifying its exploration in this research. Recent decades have seen multiple studies attempting to overcome the absence of a follicular microenvironment in IVM through the addition of exogenous growth factors, follicular fluid, and co-culture systems that use fresh oocytes, denuded oocytes, and oviduct cells to simulate an in vivo setting [14, 37, 38]. Similar to our results, Ling et al. demonstrated that MSC-conditioned medium resulted in a greater rate of mouse oocyte maturation than α-MEM. Their findings might vary from ours because of differences in MSC origin, oocyte type, and culture techniques, highlighting the importance of standardized protocols when comparing IVM outcomes across experimental models [39]. Adib et al. (2020) reported that both human testicular cell-conditioned medium and cumulus cell-conditioned medium (hCCCM) significantly improved oocyte maturation rates. However, these conditioned media were also associated with morphological alterations, including perivitelline space (PVS) enlargement and a higher incidence of irregular oocyte shape compared to control groups [40, 41]. The human umbilical cord mesenchymal stem cells significantly enhanced the maturation rates of both fresh and vitrified human oocytes. Additionally, it improved oocyte ultrastructures such as increased mitochondria-vesicle complexes, optimized cortical granule distribution, and enhanced mitochondrial–smooth endoplasmic reticulum aggregates [42]. Several studies have confirmed that oocyte morphology significantly influences embryo development, and high-quality embryos are more likely to be obtained after IVM when morphologically normal oocytes are used [43, 44]. Among the key abnormalities in the extracytoplasmic components, anomalies in the perivitelline space (PVS) are particularly notable. Some evidence suggests that an enlarged PVS may contribute to higher oocyte degeneration [44] and reduced fertilization success [45]. Interestingly, however, one study found that oocytes with PVS abnormalities exhibited a significantly higher embryo development rate compared to normal oocytes, which contrasts with earlier findings [46]. Bahrami et al. (2022) reported that granulosa cell-conditioned medium markedly enhanced IVM outcomes by increasing the proportion of oocytes reaching the MII stage, improving mitochondrial membrane potential and oocyte viability, boosting fertilization in vitrified-warmed and IVM oocytes, and regulating the expression of key maturation-related genes in MII oocytes of the mouse [47]. Another study has shown that conditioned media from equine amniotic fluid mesenchymal stem cells promote maturation of porcine oocytes by modulating the expression of critical genes involved in cumulus cell-mediated maturation, improving mitochondrial distribution, enhancing cortical granule positioning, and ultimately enhancing blastocyst quality [48]. Also, exosomes derived from human umbilical cord mesenchymal stem cells improved oocyte quality by increasing maturation rates, optimizing spindle formation, enhancing mitochondrial function, and boosting developmental potential [24]. Recent studies across multiple species demonstrate the critical role of follicular fluid-derived EVs (ffEVs) in enhancing oocyte maturation and developmental competence. In mares and porcines, follicular fluid-derived EVs significantly increased maturation rates [49, 50]. Bovine studies revealed that ffEVs from preovulatory follicles and ampullary fluid upregulated maturation-related genes and improved fertilization rates, alongside metabolic quality markers [51]. Further, equine ffEVs promoted cumulus expansion, viability, and MAPK pathway activation during maturation [52]. Additional evidence shows that ffEVs enhance embryo development and oocyte resistance to aging [53]. Collectively, these findings highlight ffEVs as conserved regulators of oocyte competence, with species-specific roles in altering gene expression. In human ffEVs isolated from mature follicles, enhanced in vitro maturation of immature oocytes [54]. Conversely, a study showed that ffEV supplementation does not improve nuclear maturation of cat oocytes in vitro [55]. The findings from our study, which demonstrated lower in vitro maturation (IVM) rates in oocytes from PCOS mice compared to controls, align with previous research highlighting the detrimental effects of the PCOS-associated follicular microenvironment on oocyte quality. Liu et al. (2023) reported that EVs derived from the follicular fluid of PCOS women significantly impaired oocyte maturation, leading to increased mitochondrial mislocalization, spindle abnormalities, and upregulated antioxidant gene expression. These observations suggest that the altered composition of follicular fluid in PCOS may contribute to oxidative stress and dysfunctional oocyte maturation, potentially explaining the reduced IVM efficiency observed in our study [56]. Supporting this notion, Madkour et al. (2018) conducted a randomized controlled trial in which supplementation of IVM media with follicular fluid and cumulus-granulosa cell secretions from non-PCOS women significantly improved the maturation rates of immature oocytes from PCOS patients [57]. Consistent with the mentioned results of oocyte maturation and quality, gene expression analysis of maturation-related genes revealed significant alterations in the expression of key regulatory genes, Map2k, Ccnb1, and Cdk1, during IVM under different experimental conditions, particularly in the context of PCOS. The observed downregulation of Map2k in the IVM and PCOS IVM groups suggests impaired MAPK/ERK signaling, a critical pathway for oocyte maturation and metabolic homeostasis. The further reduction in PCOS IVM oocytes may reflect exacerbated dysfunction in PCOS, where aberrant folliculogenesis and oxidative stress are known to disrupt signaling cascades. The restoration of Map2k expression in IVM + CM and PCOS IVM + CM groups implies that conditioned medium (CM) contains factors—possibly growth factors or extracellular vesicles—that rescue MAPK pathway activity, potentially improving oocyte competence. CCcnb1 and CDK1 suppression may contribute to maturation arrest in IVM. While the PCOS IVM group showed no further significant decline in Ccnb1, the marked reduction in Cdk1 suggests a PCOS-specific defect in the oocyte cell cycle. Notably, CM supplementation consistently upregulated both genes in PCOS IVM, reinforcing its potential to mitigate cell cycle disruptions. Although our findings demonstrate that CM and EV supplementation restored the expression of Map2k, Ccnb1, and Cdk1 in association with improved oocyte maturation, these results indicate a correlative relationship rather than direct causation. Further functional experiments, such as gene knockdown, overexpression, or pathway inhibition studies, are required to confirm whether modulation of these genes directly mediates the beneficial effects of CM and EVs on oocyte maturation and developmental competence. MSC-CM and EVs are known to contain a diverse array of bioactive molecules, including growth factors (e.g., IGF-1, EGF, VEGF), cytokines, chemokines, and regulatory microRNAs, which have been reported to modulate key signaling pathways involved in oocyte maturation, cumulus cell function, and oxidative stress regulation [58]. Several studies have highlighted that MSC-derived factors can enhance oocyte maturation and fertilization rates [39, 59]. Although the specific components responsible for the effects observed in the present study were not individually analyzed, it is likely that a combination of these molecules in CM and EVs contributes to the restoration of maturation-related gene expression and improved developmental competence. The higher efficacy of MSC CM compared to EVs in enhancing oocyte maturation likely reflects the broader and more complex composition of bioactive molecules present in CM. Unlike isolated EVs, CM contains a combination of EV-associated factors and freely soluble molecules, including growth factors, cytokines, antioxidants, and metabolites [60]. While EVs alone showed modest improvements, the components excluded from EV fractions appear critical for achieving the full effect. Taken together, these findings suggest that the superior efficacy of CM in oocyte maturation is likely due to its richer secretome, encompassing both EVs and soluble bioactive factors, which collectively provide more comprehensive support for oocyte developmental competence. Future work aimed at identifying and quantifying key factors of both hWJMSC CM compared to EVs will help clarify the precise mechanisms of MSC-CM and EVs’ action on oocyte maturation. Collectively, these results provide robust evidence that hWJMSC-derived CM and EVs are associated with enhanced oocyte developmental competence, particularly in challenging conditions like PCOS, where conventional protocols often yield poorer results. The observed restoration of Map2k, Ccnb1, and Cdk1 expression may contribute to improvements in nuclear and cytoplasmic maturation, ultimately supporting enhanced developmental potential, though direct causation remains to be confirmed. One limitation of the present study is that the assessment of developmental competence was limited to oocyte maturation parameters, including MII rate, viability, and morphometric characteristics. While these endpoints provide valuable information regarding oocyte quality, they do not fully represent the oocyte’s ability to undergo successful fertilization and support subsequent embryo development. Future studies incorporating fertilization and blastocyst formation assessments are needed to comprehensively evaluate the developmental potential of oocytes matured under the tested conditions. Also, it should be noted that NMRI mice, although capable of developing PCOS-like phenotypes under letrozole induction, are not among the most widely validated strains for this model. As an outbred strain, NMRI may introduce strain-dependent variability in endocrine and metabolic responses. Acknowledging this limitation is important for interpreting our findings and for comparing them with studies conducted in more commonly used strains such as C57BL/6 or Balb/c. Conclusion The superior performance of CM highlights its potential as an optimized supplement for IVM protocols, while EVs offer a more refined, cell-free alternative that may be advantageous for clinical translation. Future research should employ proteomic/metabolomic profiling to identify key active components in CM/EVs for developing standardized IVM treatment. These findings should then be validated in translational models, with parallel investigation of synergistic effects when combined with adjuvants like antioxidants. Such efforts will optimize IVM protocols, enhancing oocyte quality and maturation rates in both normal and PCOS conditions for clinical application. Materials and methods Ethics statement This study was conducted with approval from the Shiraz University of Medical Sciences Animal Ethics Committee (IR.SUMS.REC.1400.566) and also adhered to the guidelines set forth by the ARRIVE (Animal Research: Reporting of In Vivo Experiments) to ensure rigorous reporting, transparency, and reproducibility. Isolation and cultivation of hWJMSCs and production of hWJMSCs Umbilical cords were collected from full-term infants born by cesarean section at Hafez Hospital, after obtaining written informed consent from their parents following the protocols approved by the Ethics Committee of Shiraz University of Medical Sciences (IR.SUMS.REC.1400.566). All the processes related to the isolation and cultivation of hWJMSCs, characterization, differentiation of the cells, CM and EVs extraction were done according to a previous study [17]. After collection, the umbilical cords were immediately placed in ice-cold phosphate-buffered saline (PBS) (Shellmax, USA). The solution was supplemented with antibiotics (100 U/mL streptomycin and 100 μg/mL penicillin (Gibco, UK)). Initially, the umbilical vein was incised, followed by scraping away the endothelial lining of the vein and the amniotic epithelium, after which both arteries were removed. Later, tiny explant fragments, approximately 4 by 5 mm, were cultured in α-Minimal Essential Medium (α-MEM) (Shellmax, USA), 10% fetal bovine serum (FBS) (Gibco, UK), 1% L-glutamine (Gibco, UK), 100 U/mL penicillin (Gibco, UK), and 100 μg/mL streptomycin (Gibco, UK) in a culture dish (SPL Lifesciences, Korea). The MSCs started migrating from the explant roughly 15 days later. For the subsequent experiments, the hWJMSC from passages 3 to 6 was employed. Characterization of hWJMSCs Following the growth expansion phase, the isolated MSCs were examined under a light microscope to evaluate cell morphology. Flow cytometry-based assay To examine cell surface markers, hWJMSCs at passage three were subjected to flow cytometry. Using the 0.25% Trypsin–EDTA (Dacell, Iran), the cells were detached from the flask (NEST, China) and were subsequently centrifuged at 1200 rpm for 5 min. The cell suspension was adjusted to a final concentration of 10⁶ cells per mL in 100 μL PBS (Shell max, USA) and incubated at 4 °C with the following anti-human antibodies: CD73-PE, CD144, phycoerythrin-conjugated CD34, and CD90 for 30 min (all purchased from Abcam, UK). Cell surface staining was carried out using fluorescein isothiocyanate or phycoerythrin-conjugated isotype antibodies. Cell analysis was performed using flow cytometry and FlowJo™ software (TreeStar, Ashland, OR, USA). Differentiation into adipocytes and osteocytes Adipogenic and osteogenic differentiation media were applied to passage 3 cells for 3 and 4 weeks, respectively. A fresh medium was provided every 72 h. The adipogenic differentiation medium was composed of α-MEM (Shellmax, USA) supplemented with 100 nM dexamethasone (Sigma, USA), 50 μg/mL ascorbic acid-2 phosphate (Merck, Germany), 10% FBS (Gibco, UK), and 50 μg/mL indomethacin (Sigma, USA). The differentiation of adipocytes was examined through oil-red O staining. Initially, the cells were fixed using 4% paraformaldehyde (Merck, Germany). In the next step, staining was performed using 0.5% oil-red O (Sigma Aldrich, USA) in isopropyl alcohol (Merck, Germany). The α-MEM supplemented with 10% FBS (Kiazist, Iran), 10 nM dexamethasone (Sigma, USA), 50 μg/mL ascorbic acid-2 phosphate (Merck, Germany), 2.1604 g/L 6-glycerol phosphate, and 10 mM β-glycerophosphate (Sigma, USA) was used as the osteogenic differentiation medium. Methanol (Merck, Germany) was used to fix the cells and stained with Alizarin-red S (Sigma Aldrich, USA) to determine the MSCs’ potential to differentiate into osteoblasts and observed with an inverted phase-contrast microscope. Preparation of conditioned media Conditioned medium (CM) was prepared from human Wharton’s jelly mesenchymal stem cells (hWJMSCs). When the cells reached 70–75% confluence, the complete culture medium was removed. The cell monolayer was washed twice with phosphate-buffered saline (PBS), and serum-free medium was added. After 48 h of culture, the medium was collected and centrifuged (12,000 × g, 10 min, 4 °C). The supernatant was then processed: a fresh portion was used for extracellular vesicle (EV) isolation, and the remainder was kept in − 80 °C to be lyophilized to prepare the CM. Extraction of EVs The Exocib kit (Cib Biotech, Iran) was employed to isolate EVs from MSCs’ CM. In short, the MSCs’ CM were gathered and centrifuged at 3000 r/min for 10 min to remove cell fragments. Afterward, the supernatant and Exocib solution were mixed at a 5:1 ratio and incubated at 4 °C for 12 h at 4 °C followed by centrifugation at 3000 r/min for 40 min. Then, after discarding the supernatant, the pellet was mixed again in 100 μL of PBS. After isolation, the EVs were preserved at − 20 °C. Transmission electron microscopy (TEM) The size and shape of EVs were assessed by transmission electron microscopy (LEO 906E, Zeiss, Germany). After a 1:10 dilution in PBS (Shell max, USA), the EVs were placed on copper grids, dried at room temperature, and observed via TEM without the use of staining. ImageJ software was used to determine the size distribution of EVs (Java 1.8.0_112). Dynamic light scattering (DLS) The DLS approach allows for the measurement of particle size distributions spanning from 1 nm up to 6 μm. Particles such as EVs disperse light upon being hit by the laser beam. By analyzing changes in scattered light patterns, a mathematical model based on light scattering principles and Brownian motion was developed. Seven EV samples were assessed to calculate the average size distribution. Experiments A total of 84 NMRI female mice, aged 6–8 weeks and weighing between 30 and 35 g, were procured from the Comparative and Experimental Medicine Center at Shiraz University of Medical Sciences. The animals were housed in a controlled environment with a 12-h light/dark cycle and ambient temperatures maintained between 20 °C and 24 °C. Food and water were provided ad libitum throughout the experimental period. Monitoring the estrous cycle Before experiments, vaginal smears were collected daily between 9:00 and 10:00 AM for 2 weeks to make sure that the animals were mature and had a regular sexual cycle. Vaginal cells were collected by lavage of distilled water, fixed on a slide, and stained by Giemsa to assess the estrous cycle stages, including proestrus, estrus, metestrus, and diestrus. A duration of 4–5 days was considered the definition of regular cycles [61]. Establishment of the PCOS mouse model To induce PCOS, adult female NMRI mice received letrozole (Letrax 2.5, Abu Raihan Pharmaceutical Co, Tehran, Iran) at a dose of 90 μg/kg daily for one week by gavage. To establish a letrozole-induction protocol for NMRI mice, we tested several regimens. An initial 21-day protocol at 6 mg/kg/day caused ovarian hemorrhage, rendering COCs’ collection impossible. Also, shortening the duration at this dose yielded the same result. We then tested a lower dose (90 μg/kg/day), successful in our previous BALB/c studies, over varying durations [1–4]. Only the 7-day protocol yielded a sufficient number of COCs for collection. Therefore, this 7-day regimen was selected for all subsequent experiments. Consequently, data from the 2, 3, and 4-week pilot groups are limited to COCs’ counts (Supplementary file 1), while only the 7-day group was evaluated for histology and testosterone levels, as presented in the main manuscript. In each pilot experiment, we used five mice and examined both of their ovaries. PCOS induction confirmation To confirm the establishment of the PCOS model, the blood testosterone levels and the histology of the ovarian tissues were determined [62]. Serum testosterone assay To compare the testosterone levels between control and PCOS mice, the animals were anesthetized using a CO2 chamber. Blood samples were then obtained through cardiac puncture and immediately centrifuged at 3000 rpm for 10 min. The resulting serum samples were collected and stored at – 80 °C. Later, the testosterone concentration was determined using an enzyme-linked immunosorbent assay (ELISA) with commercially available kits (Monobind Inc., USA). Evaluation of the ovarian tissue Following blood collection, the ovaries were excised and fixed in 10% neutral buffered formalin for 5 days to ensure adequate preservation. The fixed tissues were then processed through a graded series of ethanol for dehydration, starting with 70%, followed by 80%, 90%, and two changes of absolute (100%) ethanol. Subsequently, the specimens were cleared in xylene to remove the alcohol and infiltrated with molten paraffin wax using an automated tissue processor. The processed tissues were then embedded in paraffin blocks. Serial sections were cut at a thickness of 5 µm using a rotary microtome and mounted on glass slides. For staining, mounted sections were deparaffinized in xylene and rehydrated through a descending ethanol series. Nuclear staining was performed using hematoxylin for 7 min, followed by rinsing in tap water, differentiation in 1% acid alcohol for 5 s, followed by rinsing in tap water. Cytoplasmic counterstaining was then carried out with Eosin Y for 2 min. Finally, sections were dehydrated through an ascending ethanol series, cleared in xylene, and coverslipped with a mounting medium. Different types of ovarian follicles, including primordial, primary, secondary, Graafian, atretic follicles, corpus luteum, and ovarian cysts, were counted in the prepared sections using a light microscope (Olympus, Japan). An unbiased counting method was employed where every fifth section throughout the entire ovary sections was analyzed to avoid double-counting [63, 64]. Experimental design and groups Both pregnant mare serum gonadotropin (PMSG, GONASER®, HIPRA, Amer, Spain) and human chorionic gonadotropin (hCG, Organon, Oss, The Netherlands) were administered at doses of 10 IU via intraperitoneal injection. The animals were divided into seven groups as follows: Control: mice were administered PMSG followed by hCG 48 h later. MII oocytes were collected 14 h post-hCG administration. IVM group: mice were administered PMSG. Forty-eight hours later, oocytes at the GV stage were collected and cultured for 24 h in IVM media [65]. IVM + CM group: mice were administered PMSG. Forty-eight hours later, oocytes at the GV stage were collected and cultured for 24 h in IVM media supplemented with hWJMSCs-derived conditioned media. IVM + EVs group: mice were administered PMSG. Forty-eight hours later, oocytes at the GV stage were collected and cultured for 24 h in IVM media supplemented with hWJMSCs-derived EVs. PCOS IVM group: PCOS-induced mice were administered PMSG. Forty-eight hours later, oocytes at the GV stage were collected and cultured for 24 h in IVM media. PCOS IVM + CM group: PCOS-induced mice were administered PMSG. Forty-eight hours later, oocytes at the GV stage were collected and cultured for 24 h in IVM media supplemented with hWJMSCs-derived conditioned media. PCOS IVM + EVs group: PCOS-induced mice were administered PMSG. Forty-eight hours later, oocytes at the GV stage were collected and cultured for 24 h in IVM media supplemented with hWJMSCs-EVs. Determining the optimal concentration of CM and EVs To determine the optimal concentrations of CM and EVs for IVM, the maturation rate of GV-stage oocytes was assessed in IVM medium supplemented with various doses of these supplements. Initially, the protein concentrations of hWJMSCs-derived CM or EVs were measured using the Bradford Protein Assay Kit (ProtoCib, Cib Biotech, Iran) following the manufacturer’s instructions. The protein concentrations were found to be 500 µg/ml for CM and 15 µg/ml for EVs. Following this, GV-stage oocytes were randomly assigned to seven groups and cultured for 24 h in IVM medium supplemented with different concentrations of hWJMSCs-derived CM or EVs. The optimal concentration was determined based on the oocyte maturation rate. The study identified 50 μg/ml for CM and 5 μg/ml for EVs as the most effective concentrations. COCs collection and IVM procedure In the control group, mature (MII) oocytes were harvested to serve as in vivo-matured normal oocytes for comparison with those matured in vitro. Maturity was defined by the extrusion of the first polar body. Mice were superovulated via an IP injection of PMSG, followed 48 h later by an IP injection of hCG. Fourteen hours after hCG administration, the mice were anesthetized using a CO₂ chamber. The oviducts were then transferred into handling medium (G-MOPS™, Vitrolife, Göteborg, Sweden), which was pre-incubated for 24 h at 37 °C. Under a stereomicroscope (Nikon, Tokyo, Japan), the oviducts were dissected using two insulin syringes (Helma Teb, Baspar Sanat Fakher, Saveh, Iran). The cumulus–oocyte complexes were released and collected with flame-polished Pasteur pipettes, and the complexes were placed into a few drops of hyaluronidase (80 IU/mL; Vitrolife) to separate the cumulus cells and harvest MII oocytes. In all six IVM groups, 48 h after PMSG injection, COCs were collected from ovarian dissection. The COCs were washed in handling medium and then cultured for 24 h in 50 μl droplets covered with mineral oil, under a controlled environment of 5% CO₂ at 37 °C. The culture medium consisted of basal IVM medium—Minimum Essential Medium α (α-MEM) supplemented with 0.1 IU/mL FSH (Follitropin alfa 75 IU, CinnaGen, Iran), 5 mIU/mL hCG (Folignan, DarouPakhsh, Iran), and 75 μg/mL penicillin, 50 μg/mL streptomycin, and 5% fetal bovine serum (Gibco, UK) either alone or supplemented with hWJMSCs-derived CM or EVs according to the respective experimental groups. Both mature oocytes from the control group and those obtained after IVM were used for subsequent analyses, including assessment of maturation rate, measurement of oocyte diameter, perivitelline space (PVS), and ZP thickness. Nuclear maturation was examined using orcein staining of chromatin, while oocyte viability was assessed with Trypan Blue (TB) staining. Additionally, in each group, a proportion of mature oocytes was stored at − 80 °C for gene expression profiling of CDk1, CCNB1, and MAP2K using real-time PCR. Brilliant cresyl blue (BCB) staining To assess the effects of selecting developmentally competent oocytes, the collected COCs were first washed three times with PBS. They were then exposed to 13 μM BCB in PBS at 37 °C under humidified air conditions for 90 min. After this incubation, the COCs were rinsed three times with PBS and subsequently classified as BCB-positive (BCB+, indicated by blue cytoplasm) or BCB-negative (BCB−, indicated by colorless cytoplasm) [66]. Evaluation of the oocyte maturation rate Oocyte maturation was evaluated using an inverted microscope (Nikon, Japan), and the proportions of oocytes at various stages, GV, MI, MII, or degenerated, were recorded. Mature oocytes were identified by the presence of the first polar body. For further experiments, selected oocytes exhibited a spherical shape, a well-defined zona pellucida, a clear perivitelline space, and a faintly granular cytoplasm without inclusions [59]. Examining nuclear maturation via orcein staining of chromatin Nuclear maturation of the oocytes was assessed using aceto-orcein staining, categorizing them into GV, GVBD, anaphase–telophase, and MII stages. The oocytes were placed on a glass slide and fixed using a 3:1 acetic acid–ethanol solution for 24 h. Next, the oocytes were stained with aceto-orcein and examined under an inverted microscope to assess nuclear maturation [67]. Trypan blue (TB) staining for evaluating oocyte survival Trypan blue (TB) is a dye extensively applied to stain dead cells. The principle of TB staining is that TB is negatively charged and binds only to damaged membranes. Intact cells allow the passage of very few select compounds through the membrane, and therefore do not absorb TB. MII oocytes of the control group and those from IVM groups were stained with TB. Those which did not stain are considered to be viable. In contrast, cells with damaged membranes were stained a distinctive blue color, as readily observed under a microscope [68]. Measurement of oocyte diameter, PVS and ZP thickness after IVM The MII oocytes harvested from mice in the control group and those harvested from IVM groups were imaged at 200 × magnification using a digital camera (Nikon, Tokyo, Japan) mounted on an inverted microscope (Nikon, Japan). Using image analysis software (ImageJ, ver. 1.41o; National Institutes of Health, Bethesda, MD), the diameter of each oocyte was determined by averaging the two perpendicular measurements including the ZP [69]. Also, the PVS and ZP thickness of each oocyte was measured at four different locations using ImageJ software, and the mean value of these measurements was calculated for each oocyte. Real-time RT-PCR To evaluate the expression of Cdk1, Ccnb1, and Map2k in mature oocytes, total RNA was extracted from three independent pools, each containing 25 oocytes per experimental group, using the RNX-Plus kit (Cinnagen, Iran). Gene-specific primers were designed with Primer3 software and their specificity was confirmed using NCBI Primer-BLAST. The primers (Table 4) were synthesized by Pishgam Tehran Company. Table 4Primer sequences used for real-time PCR analysisGeneSequence forward (5′–3′)Sequence reverse (5′–3′)Product size (bp)Cdk1TGCAATTCGGGAAATCTCTCTATCCATGGACAGGAACTCAAAGA116Map2kGGAGTGGTCTTCAAGGTCTCCTCCCGGATGATCTGGTTC105Ccnb1GCCTGAGCCTGAACCTTTCTGCAGGCGCACATC118β-actinTCCTGACCCTGAAGTACCCCACACGCAGCTCATTGTAGA98 Table 4Primer sequences used for real-time PCR analysisGeneSequence forward (5′–3′)Sequence reverse (5′–3′)Product size (bp)Cdk1TGCAATTCGGGAAATCTCTCTATCCATGGACAGGAACTCAAAGA116Map2kGGAGTGGTCTTCAAGGTCTCCTCCCGGATGATCTGGTTC105Ccnb1GCCTGAGCCTGAACCTTTCTGCAGGCGCACATC118β-actinTCCTGACCCTGAAGTACCCCACACGCAGCTCATTGTAGA98 Primer sequences used for real-time PCR analysis For cDNA synthesis, 100 ng of total RNA was used in a 10 µL reaction volume. The RNA was first mixed with 0.5 µg of oligo (dT)18 primer and nuclease-free water, incubated at 70 °C for 10 min, and then briefly chilled on ice. Subsequently, a master mix containing 2 µL of 5 × M-MLV buffer, 0.5 µL of dNTP mixture (10 mM each), 0.25 µL of RNase inhibitor (40 U/µL), and 0.25 µL of M-MLV Reverse Transcriptase (200 U/µL) was added. The complete reaction mixture was incubated at 42 °C for 60 min, followed by enzyme inactivation at 70 °C for 15 min. Real-time quantitative PCR was performed using SYBR Green I chemistry (SYBR® Premix Ex Taq™ II, Ampliqon) on an ABI StepOne Plus Real-Time PCR System. The experiment was performed in three independent biological replicates. Gene expression levels were quantified using the 2^(–ΔΔCT) method and are presented as mean ± standard deviation. Statistical differences between groups were determined using a one-way ANOVA [70]. Statistical analysis The data were analyzed using GraphPad Prism 9 software. After confirming the normal distribution and homogeneity of variances, an independent t-test was used to compare testosterone levels and the number of ovarian follicles between control and PCOS-induced mice. For the evaluation of IVM outcomes following the selection of oocytes with or without BCB staining, the study included ten independent biological replicates (n = 10) for each group. Within each replicate, after IVM, the percentages of oocytes at each maturation stage—germinal vesicle (GV), metaphase I (MI), metaphase II (MII), and degenerated—were calculated. The ten percentage values obtained for each maturation stage were then statistically analyzed using GraphPad Prism. The results are reported in the tables as mean % ± standard deviation (SD), derived from the mean and SD of the ten independent replicates for each group and maturation stage. Intergroup comparisons, one-way analysis of variance (ANOVA) followed by Tukey’s post hoc test, were applied. A p-value ≤ 0.05 was considered statistically significant. Supplementary Information Supplementary material 1Supplementary material 2 Supplementary material 1 Supplementary material 2